MIT 研究用微颗粒（Nanoparticles ）治疗癌症

MIT’s New MIT’s New Nanoparticles Tag Team Cancer Cells

Kyle Wagner — There are a ton of impressive applications of nanoparticles in medicine, especially cancer treatment, but MIT's new take on the process is pretty awesome. It uses two kinds of particles to do the job: one to find the tumors, the other to kick their ass.

Nanoparticles have already been used to make delivery of cancer drugs more efficient, but the use of these new scouting particles, which call the delivery particles to the site of the tumor, has increased the amount of medicine that reaches the tumors by a factor of 40 in trials.

The scouting cells (gold nanorods) work by entering the pores of tumors and heating up enough to cause a blood clotting reaction. Then the delivery particles attach themselves to an enzyme called Factor XIII, which is attracted to the site of the tumor during the clotting process.

Right now the process is still in its early phases. The research team admits that it needs to be simplified, especially because cancer patients are so prone to clotting all over their bodies, and the delivery particles will need a way to lock onto only the tumor clots. But still, even with all the challenges ahead, the idea that we're close to a cancer treatment that's forty times more efficient than what we have now is a pretty wonderful proposition.

Tag Team Cancer Cells

Kyle Wagner — There are a ton of impressive applications of nanoparticles in medicine, especially cancer treatment, but MIT's new take on the process is pretty awesome. It uses two kinds of particles to do the job: one to find the tumors, the other to kick their ass.

Nanoparticles have already been used to make delivery of cancer drugs more efficient, but the use of these new scouting particles, which call the delivery particles to the site of the tumor, has increased the amount of medicine that reaches the tumors by a factor of 40 in trials.

The scouting cells (gold nanorods) work by entering the pores of tumors and heating up enough to cause a blood clotting reaction. Then the delivery particles attach themselves to an enzyme called Factor XIII, which is attracted to the site of the tumor during the clotting process.

Right now the process is still in its early phases. The research team admits that it needs to be simplified, especially because cancer patients are so prone to clotting all over their bodies, and the delivery particles will need a way to lock onto only the tumor clots. But still, even with all the challenges ahead, the idea that we're close to a cancer treatment that's forty times more efficient than what we have now is a pretty wonderful proposition.